This is a routine scientific update with no material financial or regulatory content. Monitor for future clinical validation of the mTOR signature or any partnership announcements arising from the BIO REBOOT initiative.
Price Chart
Executive Summary
Oncotelic Therapeutics filed an 8-K to report presentations at Drug Discovery 2026 regarding its PDAOAI platform and hepatocellular carcinoma (HCC) research. The filing describes a four-gene mTOR-related signature associated with overall survival in retrospective analyses, and a BIO REBOOT initiative inviting research proposals using PDAOAI. No financial data, material agreements, or regulatory milestones were disclosed.
Key Facts
- Presented at Drug Discovery 2026 in Burlingame, CA on October 7-8, 2026
- PDAOAI platform indexes approximately 29 million PubMed abstracts
- HCC research identified a four-gene mTOR-related signature (FKBP1A, EIF4E, RRAGC, PPARGC1A) associated with overall survival in exploratory and independent Japanese cohort
- BIO REBOOT initiative invites researchers to propose projects using PDAOAI, with potential startup funding and development support
- Retrospective findings do not establish that the signature predicts treatment benefit from everolimus, Sapu003, or other mTOR-directed therapies
Financial Impact
No financial figures disclosed
Risk Factors
- Retrospective findings may not replicate in prospective studies
- No timeline or funding commitments for BIO REBOOT projects
- No regulatory or commercial milestones announced
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-046751 |
| Document: 0001493152-26-046751-index-headers.html | 0001493152-26-046751 |
| Document: 0001493152-26-046751-index.html | 0001493152-26-046751 |
| Document: 0001493152-26-046751.txt | 0001493152-26-046751 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $0.0200 | awaiting T+60 | — | $0.0200 (−0.00%) |
Oct 13, 2026 14d ago | 8-K | $0.0200 | awaiting T+60 | — | $0.0200 (−0.00%) |
Jul 14, 2026 15w ago | 8-K | $0.0400 $0.0200 | ▼ −50.00% | ▼ −52.79% | $0.0200 (−50.00%) |
Jun 29, 2026 17w ago | 8-K | $0.0400 $0.0245 | ▲ +38.75% | ▲ +42.59% | $0.0200 (+50.00%) |
May 5, 2026 25w ago | 8-K | $0.0400 $0.0400 | · 0.00% | ▼ −2.06% | $0.0200 (−50.00%) |
Apr 16, 2026 27w ago | 8-K | $0.0400 $0.0360 | ▼ −10.00% | ▼ −17.05% | $0.0200 (−50.00%) |
Apr 2, 2026 29w ago | 8-K | $0.0400 $0.0400 | · 0.00% | ▼ −14.16% | $0.0200 (−50.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers